References

The 2019 WHO classification of tumours of the digestive system

10.1111/his.13975 · 2020 · External reference

Combined hepatocellular-cholangiocarcinoma: an update

10.1016/j.jhep.2021.01.035 · 2021 · External reference

Combined hepatocellular-cholangiocarcinoma: changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis

10.3348/kjr.2020.0091 · 2020 · External reference

Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

10.2147/jhc.s159805 · 2019 · External reference

Update on the diagnosis and treatment of combined hepatocellular cholangiocarcinoma

2024 · External reference

cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

10.1002/hep.29789 · 2018 · External reference

Management of locally advanced or metastatic combined hepatocellular cholangiocarcinoma

10.3390/cancers15030988 · 2023 · External reference

Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes

10.1016/j.ccell.2019.04.007 · 2019 · External reference

Combined hepatocellular carcinoma-cholangiocarcinoma with sarcomatoid features: new insights into a rare and aggressive tumor

10.21037/jgo-24-752 · 2024 · External reference

Combined hepatocellular-cholangiocarcinoma: an update on pathology and diagnostic approach

10.3390/biomedicines10081826 · 2022 · External reference

Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma

10.3233/cbm-200643 · 2021 · External reference

The prognostic value of peripheral blood inflammatory markers in hepatocellular carcinoma treated with lenvatinib combined with PD-1 inhibitors

10.2147/jhc.s486910 · 2025 · External reference

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

10.1111/imm.13751 · 2024 · External reference

The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis

10.1016/j.hpb.2020.03.011 · 2020 · External reference

Evaluation of the American joint committee on cancer (AJCC) 8th edition staging system for hepatocellular carcinoma in 1,008 patients with curative resection

2020 · External reference

Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates

10.21037/cco.2018.07.03 · 2018 · External reference

The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

2020 · External reference

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

10.4240/wjgs.v16.i4.999 · 2024 · External reference

Carbohydrate antigen 19-9—Tumor marker: past, present, and future

10.4240/wjgs.v12.i12.468 · 2020 · External reference

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

10.1056/nejmoa1113205 · 2012 · External reference

Intratumor heterogeneity: the rosetta stone of therapy resistance

10.1016/j.ccell.2020.03.007 · 2020 · External reference

Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: a literature review

10.1016/j.asjsur.2024.02.115 · 2024 · External reference

Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?

10.21037/hbsn-21-346 · 2023 · External reference

Narrow-margin hepatectomy resulted in higher recurrence and lower overall survival for R0 resection hepatocellular carcinoma

2020 · External reference

The influence of resection margin width in patients with intrahepatic cholangiocarcinoma: a meta-analysis

10.1186/s12957-023-02901-5 · 2023 · External reference

Current evidence on posthepatectomy liver failure: comprehensive review

10.1093/bjsopen/zrac142 · 2022 · External reference

Immunity, inflammation, and cancer

10.1016/j.cell.2010.01.025 · 2010 · External reference

The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy

10.1186/s12876-022-02180-6 · 2022 · External reference

Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection

10.3748/wjg.v21.i38.10898 · 2015 · External reference

Hepatocellular carcinoma differentiation: research progress in mechanism and treatment

2021 · External reference

Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications

2020 · External reference

Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma

10.1038/s41598-025-01817-2 · 2025 · External reference

Development and validation of a nomogram to predict prognosis of patients with combined hepatocellular-cholangiocarcinoma after hepatic resection

10.7150/jca.116790 · 2025 · External reference

The predictive value of staging systems and inflammation scores for patients with combined hepatocellular cholangiocarcinoma after surgical resection: a retrospective study

10.1007/s11605-018-3756-3 · 2018 · External reference

Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 world health organization classification

10.1016/j.asjsur.2021.03.002 · 2021 · External reference

Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma

10.1016/j.ejso.2023.107279 · 2024 · External reference

Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma

2018 · External reference

Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma

10.1371/journal.pone.0240791 · 2020 · External reference

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer

10.1016/j.critrevonc.2013.03.010 · 2013 · External reference

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis

10.1093/jnci/dju124 · 2014 · External reference

Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications

10.3389/fcell.2022.938289 · 2022 · External reference

The good, the bad, and the ugly: neutrophils, angiogenesis, and cancer

10.3390/cancers14030536 · 2022 · External reference

Combined hepatocellular-cholangiocarcinoma: what the multidisciplinary team should know

10.3390/diagnostics12040890 · 2022 · External reference

Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma

10.1186/s12876-017-0584-y · 2017 · External reference

Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome

10.3748/wjg.v20.i35.12473 · 2014 · External reference

Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy

10.1186/s13027-022-00468-6 · 2022 · External reference

The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis

10.2147/ott.s150281 · 2017 · External reference

Microvascular invasion in hepatocellular carcinoma: a review of its definition, clinical significance, and comprehensive management

10.1155/2022/9567041 · 2022 · External reference

Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma

2021 · External reference

Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data

10.1016/j.ejrad.2023.110839 · 2023 · External reference

Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection

10.1093/gastro/goaa003 · 2020 · External reference

Patient outcomes in resected combined hepatocellular cholangiocarcinoma (cHCC-ICC) and intrahepatic cholangiocarcinoma: a single center study

10.3390/cancers16223878 · 2024 · External reference

Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection

10.1002/cam4.5328 · 2023 · External reference

Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?

10.1007/s00330-020-06861-2 · 2020 · External reference

Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management

10.1016/j.hbpd.2020.07.004 · 2020 · External reference

Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma

10.1002/hep.25874 · 2012 · External reference

Preoperative monocyte-to-lymphocyte ratio as a prognosis predictor after curative hepatectomy for intrahepatic cholangiocarcinoma

10.1186/s12885-024-12929-9 · 2024 · External reference

The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection

10.1038/s41598-018-20199-2 · 2018 · External reference

Tumor-associated macrophages as major immunosuppressive cells in the tumor microenvironment

10.3390/cancers16193410 · 2024 · External reference

Concepts of extracellular matrix remodelling in tumour progression and metastasis

10.1038/s41467-020-18794-x · 2020 · External reference

Macrophages in the premetastatic and metastatic niche: key functions and therapeutic directions

10.1186/s12967-025-06556-6 · 2025 · External reference